title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
abstract: This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.
authors.affiliation: Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Johnson
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Caudle
authors.affiliation: Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
authors.forename: L
authors.initials: L
authors.lastname: Gong
authors.affiliation: Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
authors.forename: M
authors.initials: M
authors.lastname: Whirl-Carrillo
authors.affiliation: Division of Clinical Pharmacology Vanderbilt Medical School, Nashville, Tennessee, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Stein
authors.affiliation: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Scott
authors.affiliation: Laboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; National Center for Genome Medicine; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Genomic Medicine Institute, Geisinger Health system, Danville, Pennsylvania, USA.
authors.forename: M T
authors.initials: MT
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
authors.forename: B F
authors.initials: BF
authors.lastname: Gage
authors.affiliation: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.|Department of Medicine and Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Kimmel
authors.affiliation: Department of Medicine, University of Chicago, Chicago, Illinois, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Perera
authors.affiliation: Intermountain Heart Institute, Intermountain Medical Center, and Department of Internal Medicine (Cardiology), University of Utah School of Medicine, Salt Lake City, Utah, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Anderson
authors.affiliation: Department of Molecular and Clinical Pharmacology; The Wolfson Centre for Personalised Medicine; Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
authors.forename: M
authors.initials: M
authors.lastname: Pirmohamed
authors.affiliation: Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.affiliation: Department of Neurology and Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors.forename: N A
authors.initials: NA
authors.lastname: Limdi
authors.affiliation: Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
authors.forename: L H
authors.initials: LH
authors.lastname: Cavallari
authors.affiliation: Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Wadelius
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D002648:Child; D065729:Cytochrome P-450 CYP2C9 / Q000235:genetics*; D000072470:Cytochrome P450 Family 4 / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics; D064417:Vitamin K Epoxide Reductases / Q000235:genetics*; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D000072470:Cytochrome P450 Family 4; C117480:CYP4F2 protein, human; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases